Lytos Technologies, Inc.

What Lytos Technologies, Inc. does

Lytos Technologies, Inc. is a private biotech platform company founded in 2018 by Dr. Bryan Berger, Professor of Chemical and Biomedical Engineering at the University of Virginia, and headquartered in Waynesboro, Virginia. The company is built around its proprietary LytosBI (Lytos Biological Intelligence) platform, which integrates computational modeling, data-driven design, and molecular biology to develop biological technologies that disrupt microbial biofilms, inactivate pathogens, and replace traditional chemical treatments. Lytos has built a portfolio of patented and patent-pending technologies — including a granted biofungicide patent and a granted Salmonella biofilm-disruption patent — and is developing them across four primary verticals: water treatment, food and agriculture, human and animal health, and diagnostic sample preparation.

The company's product surface consists of biological technologies that have demonstrated laboratory efficacy against pathogens including Listeria, Salmonella, Campylobacter, and antibiotic-resistant bacteria, as well as enzyme-based diagnostic sample preparation that breaks down biofilms to improve PCR sensitivity. Application areas range from municipal and industrial water decontamination, crop protection, and poultry safety to hospital-acquired infection prevention, cosmetics safety, and bacterial pneumonia treatment. Lytos operates in a pre-revenue state, with products at the laboratory-validation stage and not yet commercially deployed.

Lytos makes money — or intends to — through licensing and royalty arrangements and partnership-based co-development with industry, government, and institutional partners, including the USDA and the University of Virginia. Its go-to-market is enterprise-focused, using direct field sales combined with channel and institutional partnerships to translate lab-validated biology into scalable biosolutions across water, food, agriculture, and health end markets. Pricing is not publicly disclosed and is expected to be negotiated enterprise-by-enterprise depending on application, volume, and partner structure.

Name

Lytos Technologies, Inc.

Legal name

Lytos Technologies, Inc.

Website

https://lytostech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Lytos Technologies is a pre-revenue biotech platform company developing biological technologies that disrupt biofilms and kill pathogens, targeting water treatment, food and agriculture, and health applications through licensing and enterprise partnerships.

Ownership category

akta.pro rank

Product category

Biotechnology / Biosolutions

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industries

Biologicals Regulatory, Testing & Quality Assurance Services (AFABAEAO), Bioremediation & Phytoremediation (Enhanced Bioremediation, Natural Attenuation) (EUAIALAF), Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Biosolutions platform
• Biofilm disruption technology
• Antimicrobial resistance solutions
• Agricultural biotechnology
• Water treatment biosolutions

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biosolutions Licensing and Commercialization: Lytos Technologies is developing biological solutions for commercialization across water, food, agriculture, and health sectors. The company appears to be pre-revenue, focused on advancing laboratory-validated technologies into application-aligned biosolutions designed for future scalability.
2. Partnership-Based Development: Working with industry, government, and institutional partners to define practical requirements and advance biological technologies. Revenue may be derived through partnership agreements, co-development deals, or licensing arrangements with commercial partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Lytos Technologies develops and commercializes biological solutions through its proprietary LytosBI platform, which integrates computational modeling, data-driven design, and molecular biology to engineer technologies that disrupt biofilms, inactivate pathogens (Listeria, Salmonella, Campylobacter), and provide antifungal and antimicrobial-resistant bacteria solutions. The company is pre-revenue and translates laboratory-validated biological discoveries into scalable biosolutions for water treatment, food and agriculture, and health sector customers.

Product overview

Lytos Technologies is a biosolutions platform company built around its proprietary LytosBI™ (Lytos Biological Intelligence) platform, which integrates computational modeling, data-driven design, and molecular biology to develop and validate biological technologies. The platform enables targeted solutions across water safety and quality, food safety and agriculture, and health applications including biofilm disruption, pathogen inactivation (Listeria, Salmonella, Campylobacter), antifungal technologies, diagnostic sample preparation, and antibiotic-resistant bacteria treatment. The company operates from discovery through application-aligned biosolution development, working with industry, government, and institutional partners to translate laboratory-validated biology into scalable, real-world impact.

Differentiator

Problem solved

Functional benefit

Brands

• LytosBI™: The proprietary biosolutions platform that integrates computational modeling, data-driven design, and molecular biology to accelerate biological invention. Developed by Dr. Berger and the Lytos scientific and product development team.

Products and services

• LytosBI™ (Lytos Biological Intelligence) Platform

Quantifiable outcome

• Demonstrated activity against Campylobacter in laboratory studies, pointing toward future water-treatment solutions
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• University of VirginiacoreStrategic or Co-development PartnerUniversity of Virginia is the foundational research partner, where founder Dr. Bryan Berger serves as Professor of Chemical and Biomedical Engineering. The company's founding science was discovered at UVA, and the institution continues as a key collaborative partner for ongoing research and development of biological technologies.
• USDAcoreStrategic or Co-development PartnerThe USDA is a key government partner collaborating with Lytos on agricultural applications of biological technologies. The partnership supports development of bio-based solutions for crop protection, food safety, and sustainable agriculture.
• Industry PartnerscoreStrategic or Co-development PartnerLytos works with industry partners to identify unmet needs and translate laboratory-validated technologies into scalable biosolutions. These partnerships ensure biological technologies are aligned with practical requirements from safety and performance to manufacturability and deployment.
• Government PartnerscoreStrategic or Co-development PartnerCollaborative partnerships with government entities to advance biological solutions for public health, water safety, and agricultural applications. Government partnerships help ensure solutions meet regulatory requirements and public health standards.
• Institutional PartnerscoreStrategic or Co-development PartnerLytos works with institutional partners including academic and research institutions to advance biological technologies. These collaborations help ensure science is translated into practical solutions that work in real-world environments.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AgBiome: Agricultural biotech developing biological crop protection products from microbial collections. Directly comparable to Lytos in the agricultural-biologicals vertical, particularly on biofungicide and bio-pesticide applications.
• Pivot Bio: Ag-biologicals company replacing synthetic nitrogen fertilizers with engineered microbial nitrogen-fixing probiotics. Comparable to Lytos as an ag-biologicals platform using proprietary microbial technology to displace traditional chemical inputs.
• BioVersys: Swiss clinical-stage biotech developing small-molecule and biological therapeutics to combat antimicrobial resistance. Directly comparable to Lytos as a biotech tackling AMR through novel mechanisms, though focused more on small-molecule therapeutics than biofilm-disrupting biology.
• Locus Biosciences: Clinical-stage biotech engineering bacteriophage and CRISPR-based precision antimicrobials to target antibiotic-resistant bacteria and biofilm-associated infections. Highly comparable to Lytos in addressing AMR through engineered biology, with a more advanced clinical pipeline.
• Eligo Bioscience: French biotech developing 'Eligobiotics' — engineered phage payloads designed to selectively kill antibiotic-resistant bacteria in the microbiome. Closely comparable to Lytos in deploying biology to overcome microbial defenses and AMR.
• SNIPR Biome: Clinical-stage biotech developing CRISPR-based microbial medicines to selectively target antibiotic-resistant bacteria in the gut and other sites. Directly comparable to Lytos on the AMR-biology interface, though focused on human therapeutic applications.

Emerging players

• Indigo Ag: Agritech company developing microbial seed treatments and digital agronomy. Comparable to Lytos in the agricultural-biologicals vertical, with broader digital and sustainability positioning.
• Resolution Biosciences: Diagnostic and sample-preparation technology developer focused on improving sensitivity of nucleic-acid-based detection. Comparable to Lytos in the diagnostic-sample-prep vertical, particularly the enzyme-based PCR sensitivity work, though at a more advanced commercialization stage.

Broad incumbents

• Novonesis (Novozymes + Chr. Hansen): Global biosolutions incumbent producing enzymes, microbials, and cultures for food, agriculture, water, and health applications. Comparable to Lytos in targeting the same end markets with biological solutions, but as a deeply established commercial player.
• Ginkgo Bioworks: Large synthetic biology platform company developing engineered microorganisms across agriculture, food, and industrial biotech. Comparable to Lytos as a platform biology play, though operating at vastly larger scale and broader scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/lytostech

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lytos Technologies, Inc.